- Home
- FRME vs BLTE Comparison
FRME vs BLTE Comparison
Compare FRME & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- BLTE
- Stock Information
- Founded
- FRME 1893
- BLTE 2018
- Country
- FRME United States
- BLTE United States
- Employees
- FRME N/A
- BLTE N/A
- Industry
- FRME Major Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- BLTE Health Care
- Exchange
- FRME Nasdaq
- BLTE Nasdaq
- Market Cap
- FRME 2.0B
- BLTE 2.1B
- IPO Year
- FRME N/A
- BLTE 2022
- Fundamental
- Price
- FRME $35.53
- BLTE $56.40
- Analyst Decision
- FRME Buy
- BLTE Strong Buy
- Analyst Count
- FRME 5
- BLTE 4
- Target Price
- FRME $46.70
- BLTE $96.67
- AVG Volume (30 Days)
- FRME 389.4K
- BLTE 37.7K
- Earning Date
- FRME 04-24-2025
- BLTE 05-12-2025
- Dividend Yield
- FRME 3.94%
- BLTE N/A
- EPS Growth
- FRME N/A
- BLTE N/A
- EPS
- FRME 3.41
- BLTE N/A
- Revenue
- FRME $610,994,000.00
- BLTE N/A
- Revenue This Year
- FRME $17.34
- BLTE N/A
- Revenue Next Year
- FRME $3.94
- BLTE N/A
- P/E Ratio
- FRME $10.42
- BLTE N/A
- Revenue Growth
- FRME N/A
- BLTE N/A
- 52 Week Low
- FRME $30.55
- BLTE $32.25
- 52 Week High
- FRME $46.13
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- FRME 36.69
- BLTE 39.21
- Support Level
- FRME $33.43
- BLTE $49.00
- Resistance Level
- FRME $37.76
- BLTE $60.21
- Average True Range (ATR)
- FRME 1.73
- BLTE 3.55
- MACD
- FRME -0.13
- BLTE -0.57
- Stochastic Oscillator
- FRME 31.58
- BLTE 41.67
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.